Related Experiment Video
Updated: Jan 1, 2026
MicroRNA In situ Hybridization for Formalin Fixed Kidney Tissues
Published on: November 30, 2013
TGF-β and microRNA Interplay in Genitourinary Cancers
Joanna Boguslawska1, Piotr Kryst2, Slawomir Poletajew2
1Department of Biochemistry and Molecular Biology, Centre of Postgraduate Medical Education; 01-813 Warsaw, Poland.
Abstract:
Genitourinary cancers (GCs) include a large group of different types of tumors localizing to the kidney, bladder, prostate, testis, and penis. Despite highly divergent molecular patterns, most GCs share commonly disturbed signaling pathways that involve the activity of TGF-β (transforming growth factor beta). TGF-β is a pleiotropic cytokine that regulates key cancer-related molecular and cellular processes, including proliferation, migration, invasion, apoptosis, and chemoresistance. The understanding of the mechanisms of TGF-β actions in cancer is hindered by the "TGF-β paradox" in which early stages of cancerogenic process are suppressed by TGF-β while advanced stages are stimulated by its activity. A growing body of evidence suggests that these paradoxical TGF-β actions could result from the interplay with microRNAs: Short, non-coding RNAs that regulate gene expression by binding to target transcripts and inducing mRNA degradation or inhibition of translation. Here, we discuss the current knowledge of TGF-β signaling in GCs. Importantly, TGF-β signaling and microRNA-mediated regulation of gene expression often act in complicated feedback circuits that involve other crucial regulators of cancer progression (e.g., androgen receptor). Furthermore, recently published in vitro and in vivo studies clearly indicate that the interplay between microRNAs and the TGF-β signaling pathway offers new potential treatment options for GC patients.
Insights
Transforming growth factor beta (TGF-β) plays a dual role in genitourinary cancers (GCs), with microRNAs potentially resolving this paradox. This interaction offers novel therapeutic strategies for GC patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Genitourinary cancers (GCs) encompass diverse tumors affecting the kidney, bladder, prostate, testis, and penis.
- Transforming growth factor beta (TGF-β) signaling is frequently dysregulated across various GCs, impacting key cancer processes.
- The "TGF-β paradox" describes TGF-β's context-dependent roles, suppressing early cancer but promoting advanced stages.
Purpose of the Study:
- To review the current understanding of TGF-β signaling in genitourinary cancers.
- To explore the role of microRNAs in mediating TGF-β's paradoxical effects in GCs.
- To highlight potential therapeutic avenues arising from the interplay between TGF-β and microRNAs in GCs.
Main Methods:
- Literature review of existing in vitro and in vivo studies on TGF-β signaling and microRNAs in GCs.
- Analysis of molecular mechanisms underlying TGF-β pathway activation and its regulation by microRNAs.
- Discussion of feedback circuits involving TGF-β, microRNAs, and other cancer regulators like the androgen receptor.
Main Results:
- TGF-β influences critical cancer cell behaviors including proliferation, migration, invasion, apoptosis, and chemoresistance in GCs.
- MicroRNAs interact with TGF-β signaling pathways, potentially explaining the observed "TGF-β paradox".
- Complex feedback loops exist between TGF-β signaling, microRNA regulation, and other cancer drivers (e.g., androgen receptor).
Conclusions:
- The intricate interplay between TGF-β signaling and microRNAs presents promising targets for novel GC therapies.
- Understanding these molecular interactions is crucial for developing effective treatment strategies for genitourinary cancer patients.
- Targeting the TGF-β/microRNA axis may offer a new paradigm for managing advanced GCs.
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs
01:16TGF - β Signaling Pathway
02:17The Tumor Microenvironment